Comparing the efficacy of generic Imatinib formulations with the original Imatinib as the frontline tyrosine kinase inhibitor in chronic phase chronic myeloid leukemia.

Published on May 20, 2015in Journal of Clinical Oncology28.349
· DOI :10.1200/JCO.2015.33.15_SUPPL.E18024
Fatih Demirkan13
Estimated H-index: 13
(Dokuz Eylül University),
Omur Gokmen Sevindik4
Estimated H-index: 4
(Dokuz Eylül University)
+ 3 AuthorsGüner Hayri Özsan6
Estimated H-index: 6
(Dokuz Eylül University)
e18024 Background: Tyrosine kinase inhibitors are the mainstay of treatment of chronic myeloid leukemia (CML). Recently, four different generic Imatinib formulations were approved for the frontline...
  • References (0)
  • Citations (2)
📖 Papers frequently viewed together
17 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
Cited By2
#1Ahmet Emre Eskazan (Istanbul University)H-Index: 10
#2Teoman Soysal (Istanbul University)H-Index: 13
As imatinib becomes generic, physicians treating patients with chronic myeloid leukemia (CML) worldwide face doubts regarding the efficacy and toxicity of generics.[1][1] There are many studies, mostly retrospective in nature, from different countries with different outcomes.[2][2] Since generics
#1J GeisslerH-Index: 1
#2Giora SharfH-Index: 5
Last. V VenkateshH-Index: 1
view all 7 authors...
Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer
6 CitationsSource